2025 Q4 -tulosraportti
Vain PDF
126 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenInteresting read before the R&D webcast on September 1st This article came out today and is worth reading for everyone who follows Circio and circRNA: "RNA's comeback tour – Cell & Gene Therapy Review" https://www.cellgenetherapyreview.com/3975-Featured-Articles/627533-RNA-s-comeback-tour/ The interesting thing is not just that circRNA is mentioned, but how the entire RNA landscape is described as entering a new phase – especially within delivery, in vivo cell engineering, and in vivo CAR-T. The article highlights, among other things: • BMS bought Orbital for $1.5 billion • Lilly bought Orna for up to $2.4 billion • J&J paid $785 million upfront to Sail and received an option for an additional $2.58 billion • Several large pharma players are investing heavily in RNA + LNP + in vivo cell engineering And then Circio comes in as a slightly different variant. Wiklund points to the difference between regular mRNA/circRNA which is delivered ready in a dose, and circVec where the cell itself continuously produces and circularizes RNA. The article also mentions Circio's reported up to six months of expression in lymphocytes in vivo. Even more interesting is the comment that Circio is now testing circVec together with Acuitas and other delivery companies to combine the long expression profile with targeted delivery. It is precisely this combination that I find interesting to follow going forward: delivery → cell-specificity → expression → duration → effect → safety If Circio manages to document that circVec can actually provide a significant advantage on these points, one begins to approach a platform that can potentially be used across several programs – not just a single candidate. And that makes the webcast on September 1st extra interesting, especially since Circio itself has said that they will come with new data and a comprehensive R&D, BD, and financial update. It will be exciting to see how much of this actually begins to materialize in data.
·5 t sitten · MuokattuToday's large price swings and 103 mill in turnover can be interpreted positively. The reaction triggered by Moderna news in the USA shows how sensitive the market now is to news in Circio. When a non-company-specific news from the USA makes investors press the buy button, what do you think happens when concrete news arrives in about 1 week in Circio itself???? 😊
·5 t sittenMany waiting for news here? I have received all the news I need. Unique results in tests, cooperation agreements with both Spanish and American universities, and cooperation with others in the industry. I'm just waiting for 1 new big piece of news. Acquisition! And when it comes, it's too late to jump on the train. Or should we say the rocket. While I wait for this news, I'm filling up with every spare krone. Everything under 20 kr is cheap!!
Anyway, it's boring to be those who sold modena for 60 dollars yesterday when it opened like it did today. Absolutely wild how high the turnover has been today. Here, the potential is not just 150% up when the clock ticks 09:00 in the morning, but potentially higher with the right news. As Erik said 6 months back, this will go 10-bagger.- ·7 t sittenAn unhealthy culture has been created in this stock. People are unable to value the company and traders are running wild due to an interest.
It has become a widespread negative culture that some here try to dictate what people should think, and now people are also expected to value the company .. you can think absolutely what you want , but interfering with what people who own this stock do ... .. that's just not okay. - ·8 t sittenWe can hope that Circio will come with news of the same caliber sometime in the future.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
126 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenInteresting read before the R&D webcast on September 1st This article came out today and is worth reading for everyone who follows Circio and circRNA: "RNA's comeback tour – Cell & Gene Therapy Review" https://www.cellgenetherapyreview.com/3975-Featured-Articles/627533-RNA-s-comeback-tour/ The interesting thing is not just that circRNA is mentioned, but how the entire RNA landscape is described as entering a new phase – especially within delivery, in vivo cell engineering, and in vivo CAR-T. The article highlights, among other things: • BMS bought Orbital for $1.5 billion • Lilly bought Orna for up to $2.4 billion • J&J paid $785 million upfront to Sail and received an option for an additional $2.58 billion • Several large pharma players are investing heavily in RNA + LNP + in vivo cell engineering And then Circio comes in as a slightly different variant. Wiklund points to the difference between regular mRNA/circRNA which is delivered ready in a dose, and circVec where the cell itself continuously produces and circularizes RNA. The article also mentions Circio's reported up to six months of expression in lymphocytes in vivo. Even more interesting is the comment that Circio is now testing circVec together with Acuitas and other delivery companies to combine the long expression profile with targeted delivery. It is precisely this combination that I find interesting to follow going forward: delivery → cell-specificity → expression → duration → effect → safety If Circio manages to document that circVec can actually provide a significant advantage on these points, one begins to approach a platform that can potentially be used across several programs – not just a single candidate. And that makes the webcast on September 1st extra interesting, especially since Circio itself has said that they will come with new data and a comprehensive R&D, BD, and financial update. It will be exciting to see how much of this actually begins to materialize in data.
- ·5 t sitten · MuokattuToday's large price swings and 103 mill in turnover can be interpreted positively. The reaction triggered by Moderna news in the USA shows how sensitive the market now is to news in Circio. When a non-company-specific news from the USA makes investors press the buy button, what do you think happens when concrete news arrives in about 1 week in Circio itself???? 😊
- ·5 t sittenMany waiting for news here? I have received all the news I need. Unique results in tests, cooperation agreements with both Spanish and American universities, and cooperation with others in the industry. I'm just waiting for 1 new big piece of news. Acquisition! And when it comes, it's too late to jump on the train. Or should we say the rocket. While I wait for this news, I'm filling up with every spare krone. Everything under 20 kr is cheap!!Anyway, it's boring to be those who sold modena for 60 dollars yesterday when it opened like it did today. Absolutely wild how high the turnover has been today. Here, the potential is not just 150% up when the clock ticks 09:00 in the morning, but potentially higher with the right news. As Erik said 6 months back, this will go 10-bagger.
- ·7 t sittenAn unhealthy culture has been created in this stock. People are unable to value the company and traders are running wild due to an interest.It has become a widespread negative culture that some here try to dictate what people should think, and now people are also expected to value the company .. you can think absolutely what you want , but interfering with what people who own this stock do ... .. that's just not okay.
- ·8 t sittenWe can hope that Circio will come with news of the same caliber sometime in the future.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
126 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenInteresting read before the R&D webcast on September 1st This article came out today and is worth reading for everyone who follows Circio and circRNA: "RNA's comeback tour – Cell & Gene Therapy Review" https://www.cellgenetherapyreview.com/3975-Featured-Articles/627533-RNA-s-comeback-tour/ The interesting thing is not just that circRNA is mentioned, but how the entire RNA landscape is described as entering a new phase – especially within delivery, in vivo cell engineering, and in vivo CAR-T. The article highlights, among other things: • BMS bought Orbital for $1.5 billion • Lilly bought Orna for up to $2.4 billion • J&J paid $785 million upfront to Sail and received an option for an additional $2.58 billion • Several large pharma players are investing heavily in RNA + LNP + in vivo cell engineering And then Circio comes in as a slightly different variant. Wiklund points to the difference between regular mRNA/circRNA which is delivered ready in a dose, and circVec where the cell itself continuously produces and circularizes RNA. The article also mentions Circio's reported up to six months of expression in lymphocytes in vivo. Even more interesting is the comment that Circio is now testing circVec together with Acuitas and other delivery companies to combine the long expression profile with targeted delivery. It is precisely this combination that I find interesting to follow going forward: delivery → cell-specificity → expression → duration → effect → safety If Circio manages to document that circVec can actually provide a significant advantage on these points, one begins to approach a platform that can potentially be used across several programs – not just a single candidate. And that makes the webcast on September 1st extra interesting, especially since Circio itself has said that they will come with new data and a comprehensive R&D, BD, and financial update. It will be exciting to see how much of this actually begins to materialize in data.
- ·5 t sitten · MuokattuToday's large price swings and 103 mill in turnover can be interpreted positively. The reaction triggered by Moderna news in the USA shows how sensitive the market now is to news in Circio. When a non-company-specific news from the USA makes investors press the buy button, what do you think happens when concrete news arrives in about 1 week in Circio itself???? 😊
- ·5 t sittenMany waiting for news here? I have received all the news I need. Unique results in tests, cooperation agreements with both Spanish and American universities, and cooperation with others in the industry. I'm just waiting for 1 new big piece of news. Acquisition! And when it comes, it's too late to jump on the train. Or should we say the rocket. While I wait for this news, I'm filling up with every spare krone. Everything under 20 kr is cheap!!Anyway, it's boring to be those who sold modena for 60 dollars yesterday when it opened like it did today. Absolutely wild how high the turnover has been today. Here, the potential is not just 150% up when the clock ticks 09:00 in the morning, but potentially higher with the right news. As Erik said 6 months back, this will go 10-bagger.
- ·7 t sittenAn unhealthy culture has been created in this stock. People are unable to value the company and traders are running wild due to an interest.It has become a widespread negative culture that some here try to dictate what people should think, and now people are also expected to value the company .. you can think absolutely what you want , but interfering with what people who own this stock do ... .. that's just not okay.
- ·8 t sittenWe can hope that Circio will come with news of the same caliber sometime in the future.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt